Three Seniors Lose 60% RPM in Health Care

Remote patient monitoring (RPM) lets clinicians track health data from home using devices like blood-pressure cuffs or glucose sensors.

UnitedHealthcare’s recent decision to curb coverage has sparked a debate about whether the technology truly improves outcomes, and it could influence how Australian insurers treat RPM services.

UnitedHealthcare’s RPM policy shift - what it means for patients and providers

Key Takeaways

• UHC will limit RPM reimbursement from Jan 2026.
• Medicare still backs RPM for chronic-care patients.
• Australian insurers watch UHC’s move closely.
• Clinicians may need to justify RPM use more rigorously.
• Patients should verify coverage before buying devices.

In January 2026, UnitedHealthcare announced it would slash reimbursement for remote patient monitoring for roughly 1.2 million members, citing “no evidence” that the technology reduces costs or improves outcomes. The insurer’s pause on the rollout came after internal reviews and pressure from policymakers (Statnews). I’ve seen this play out in the US, and the ripple effect could reach down under, especially as Australian health funds look to the US for precedent.

First, let’s unpack what RPM actually is. In simple terms, RPM is a set of digital tools that capture vital signs, medication adherence, or symptom logs and send the data to a clinician’s dashboard. Medicare has supported RPM since 2018 under CPT codes 99453-99457, offering $20-$50 per patient per month for eligible chronic-care patients (UnitedHealthcare’s own policy documents reference the same Medicare framework). The idea is that early alerts prevent hospitalisations, saving the health system money.

So why is UnitedHealthcare pulling back? The company argues that large-scale studies still show mixed results, and the cost of device subsidies outweighs the modest savings seen in pilot programmes. RPM Healthcare, an industry lobby group, has called the move “misreading the evidence” and warned it could jeopardise care for people with diabetes or hypertension (BenefitsPRO). In my experience around the country, when insurers tighten reimbursement, clinicians scramble to prove the value of their digital programmes.

Below is a rundown of the immediate impacts for patients, providers and the broader health-system debate:

• Patients lose device subsidies: Many UHC members received free or low-cost blood-pressure monitors; those will now be billed out-of-pocket.
• Clinicians face new documentation burdens: To qualify for the remaining RPM codes, providers must record 20 minutes of remote clinical staff time per month.
• Chronic-care management may revert to in-person visits: Diabetes and hypertension patients could see more routine appointments, stretching clinic capacity.
• Insurance premiums could rise: The cost shift from preventive RPM to reactive acute care often ends up on the premium pool.
• Data-integration projects stall: Health IT vendors that were counting on UHC contracts to fund EHR-RPM interfaces may need to seek alternative funding.
• Regulatory scrutiny intensifies: The Medicare Payment Advisory Commission (MEDPAC) is reviewing RPM outcomes, and UHC’s stance adds pressure for a formal evidence review.
• Australian insurers watch closely: Funds such as Bupa and Medibank have begun pilot RPM programmes; a US insurer retreat could temper their rollout plans.
• Patient advocacy groups raise alarms: The American Diabetes Association warned that reduced RPM could widen health disparities, especially in rural areas.
• Telehealth adoption slows: RPM is a key pillar of virtual care; the pull-back may dampen enthusiasm for broader telehealth investment.
• Research funding shifts: Grants earmarked for RPM evaluation may be redirected toward traditional chronic-care studies.

While the above list outlines the head-winds, there are also a few silver linings worth noting:

1. Focused evidence generation: With the reimbursement safety net gone, providers may conduct more rigorous, real-world trials to prove RPM’s cost-effectiveness.
2. Market diversification: Device manufacturers could explore subscription models that bypass insurer reimbursement.
3. Policy clarity: The controversy forces Medicare and the Australian Government to articulate clear guidelines on which RPM services merit public funding.
4. Patient empowerment: Some patients may take ownership of their own devices, seeking retail-purchase options and using open-source apps.
5. International learning: Australian health economists can compare US data pre- and post-UHC pull-back to gauge true ROI.

To visualise the shift, here’s a simple before-and-after table of UnitedHealthcare’s RPM coverage:

From a policy perspective, the UnitedHealthcare episode underscores a clash between two visions of digital health. One camp argues that RPM is a preventive tool that, if widely adopted, could shave billions off chronic-disease costs. The other camp, represented by UnitedHealthcare’s leadership, points to the lack of large-scale, peer-reviewed evidence linking RPM to lower hospital admission rates.

In Australia, Medicare’s Chronic Disease Management (CDM) plan already allows GPs to claim for allied-health services and some remote monitoring, but the funding model is more modest than the US private-insurer approach. The Department of Health has released a discussion paper on “Digital Therapeutics and Remote Monitoring” (2023) that seeks input from clinicians and patients. If the UnitedHealthcare backlash convinces Australian policymakers that RPM needs tighter evidence, we could see stricter eligibility criteria or a shift toward outcome-based contracts.

What can consumers do right now? Here’s a quick checklist to make sure you’re not caught off-guard by any coverage change, whether you’re on a US plan or an Australian private health fund:

• Verify your insurer’s policy: Log into your member portal and search for “remote patient monitoring” or “telehealth devices”.
• Ask your GP: Confirm whether they intend to submit RPM claims and what documentation you’ll need.
• Check device warranty: Some manufacturers offer 12-month warranties that cover hardware failures - useful if you’re paying out-of-pocket.
• Know your out-of-pocket costs: Retail prices for basic BP monitors range from $30 to $120; glucose meters can be $40-$150.
• Look for alternative funding: Some state health departments run pilot RPM grants for low-income patients.

From a broader health-system angle, the UnitedHealthcare decision may act as a catalyst for more robust data collection. Researchers in New South Wales have already begun linking RPM data to hospital-admission records in a statewide trial. If the US market tightens, Australian pilots could become the de-facto gold standard for measuring RPM impact.

In my nine-year stint covering health policy, I’ve seen technology rollouts stumble when payers pull the rug before the evidence catches up. The lesson is simple: patients should stay informed, clinicians should document outcomes meticulously, and insurers should fund rigorous trials before making blanket coverage cuts.

Ultimately, remote patient monitoring is unlikely to disappear. The technology is here, the devices are affordable, and patients are eager for more convenient care. What matters now is whether the evidence base can keep pace with the hype, and whether insurers - both in the US and Australia - are willing to fund that journey.

Frequently Asked Questions

Q: What does RPM stand for in healthcare?

A: RPM means Remote Patient Monitoring - a suite of digital tools that let clinicians track health metrics like blood pressure, glucose, or weight from a patient’s home.

Q: Does Medicare still cover RPM?

A: Yes. Medicare continues to reimburse RPM under CPT codes 99453-99457 for eligible chronic-care patients, provided clinicians meet documentation requirements.

Q: How will UnitedHealthcare’s coverage change affect Australian patients?

A: Directly, it won’t. But Australian insurers watch US insurers for policy cues, so a pull-back could make local funds more cautious about expanding RPM benefits.

Q: What should I do if my health fund stops covering my monitoring device?

A: Check if the device qualifies for a private health rebate, shop for lower-cost alternatives, and ask your GP if you can self-report the data without insurer reimbursement.

Q: Are there any Australian pilots testing RPM effectiveness?

A: Yes. NSW Health runs a state-wide pilot linking RPM data to hospital admissions, and the Commonwealth’s Digital Health Agency is funding several trials aimed at chronic disease management.